Tandem Diabetes Care
An American medical-device company developing insulin pumps, automated insulin-delivery systems, and diabetes-management software.
Last updated October 14, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Tandem Diabetes Care is a San Diego-based medical-device company focused on insulin-delivery technology for people who require intensive insulin therapy. Its principal platforms are the t:slim X2 and Tandem Mobi insulin pumps, supported by continuous glucose monitoring integrations, automated insulin-delivery algorithms, infusion sets, and digital diabetes-management tools. The company positions its products around improving usability, interoperability, software updatability, and automated glucose control rather than treating the pump as a standalone hardware device. The business was incorporated in January 2006 under the name Phluid, Inc. and adopted the Tandem Diabetes Care name in 2008. Its early product concept was shaped by interviews with insulin-pump users and clinicians. The resulting t:slim pump used a color touchscreen and a rechargeable form factor, distinguishing it from many contemporaneous pumps that relied primarily on physical buttons. The U.S. Food and Drug Administration cleared the t:slim insulin-delivery system in November 2011, and Tandem began commercial sales in the United States in 2012. Tandem became a Nasdaq-listed company in 2013. Its first-generation t:slim platform was followed by the t:slim G4, which combined pump functions with display of Dexcom continuous glucose-monitoring data, and then by the software-updatable t:slim X2. The X2 platform allowed compatible pumps to receive certain software improvements without replacement of the hardware. It subsequently supported Dexcom G5 and G6 integrations and, in some markets, FreeStyle Libre connectivity. The company expanded from conventional pump delivery into automated insulin delivery. Basal-IQ, introduced in 2018, used predicted sensor glucose values to suspend insulin when a low was anticipated. Control-IQ, authorized by the FDA in December 2019 and launched in the United States in January 2020, used a model-predictive algorithm to adjust basal insulin and deliver automatic correction boluses when used with compatible glucose sensors. Although the system automates important parts of insulin delivery, users still configure therapy settings and generally announce meals. Tandem has also broadened its technology portfolio through software and acquisitions. It acquired Sugarmate, a diabetes-data and alert application, in 2020; Capillary Biomedical, an infusion-set developer, in 2022; and Swiss patch-pump developer AMF Medical in 2023. AMF's Sigi rechargeable patch-pump technology remained under development in the available reference material. The smaller Tandem Mobi pump received U.S. FDA clearance in July 2023 and began a full U.S. launch in February 2024. It is designed to be worn on the body or carried in clothing, uses a 200-unit cartridge, and is operated mainly through a compatible smartphone application while retaining a physical button for a preset bolus. Tandem's software portfolio includes t:connect, Tandem Source, and Sugarmate. These tools allow patients and clinicians to review pump and glucose information, while compatible configurations can support phone-based bolus delivery. The company's products are regulated medical devices and therefore subject to post-market safety monitoring, software corrections, and recalls. Available regulatory records describe recalls involving cartridges, the t:connect iOS application, Control-IQ+ software, and pump hardware or firmware. Tandem continues to compete in the connected insulin-pump and automated insulin-delivery market, with its strategy centered on integrated pump-and-CGM ecosystems and iterative software improvements. Tandem Diabetes is the consumer-facing brand associated with Tandem Diabetes Care, Inc., a United States medical-device company headquartered in San Diego, California. Its business is centered on insulin-delivery systems and related diabetes-management technology. The company presents its products as designed to bring greater convenience, usability, and connectivity to insulin therapy rather than treating diabetes solely through conventional standalone medical equipment. The brand’s principal offering is the t:slim X2 insulin pump. This is an insulin-delivery device intended for people who require pump-based diabetes management. Tandem also describes its business more broadly as encompassing products and services that support insulin delivery and diabetes care. Its portfolio therefore extends beyond the physical pump to include software and connected-management components associated with the use of its systems, although the available reference material does not provide a complete product catalog or detailed chronology of individual releases. Tandem Diabetes operates in the medical-technology sector, specifically the diabetes-care and insulin-delivery segment. Its positioning combines clinical utility with consumer-oriented design priorities such as convenience and style. This differentiates the brand from a purely hospital-equipment identity: the company communicates directly with people managing diabetes in daily life, as well as with the healthcare professionals and distribution channels involved in their care. The company is listed under the ticker TNDM and operates in the United States and international markets. The supplied reference material does not establish a founding year, founder, parent company, current executives, financial figures, or a complete international market list, so those details are not asserted here. Similarly, no reliable reference material supplied for this dossier identifies material campaigns, scandals, litigation, recalls, mergers, or leadership changes that can be included without additional verification. Tandem’s brand identity is consequently anchored in connected insulin delivery and diabetes-management innovation. Its flagship t:slim X2 pump provides the clearest expression of that identity, while the broader brand promise concerns making insulin therapy more usable and integrated into everyday diabetes management. Tandem remains an active public medical-device brand, but a fuller encyclopedia entry would require authoritative corporate filings, regulatory records, product documentation, and independent historical sources.
History
Tandem Diabetes Care was incorporated in January 2006 as Phluid, Inc. and changed its name to Tandem Diabetes Care in 2008. Kim Blickenstaff, a former Biosite executive, joined the company as president and chief executive officer in 2007. Tandem's initial design work was based on interviews with people who used insulin pumps and with clinicians. The company sought to make pump therapy less cumbersome through a color touchscreen, rechargeable hardware, and a more consumer-oriented interface. The FDA cleared Tandem's first t:slim insulin-delivery system in November 2011. Commercial sales in the United States began in 2012. The pump used a 300-unit insulin cartridge and touchscreen operation, differentiating it from many button-controlled pumps. Tandem went public on Nasdaq in 2013. Its subsequent product development combined pump hardware with continuous glucose-monitoring connectivity and software services. The t:slim G4, approved in 2015, added display of Dexcom G4 Platinum CGM data. Tandem began shipping the software-updatable t:slim X2 in 2016. The X2 became the company's principal pump platform and later supported integrations with Dexcom sensors and, in some markets, Abbott FreeStyle Libre systems. In 2018, Tandem introduced Basal-IQ, which used predicted glucose values to suspend insulin delivery when a low was anticipated and resume delivery after recovery. A major regulatory and technological milestone arrived with Control-IQ. In December 2019, the FDA authorized the system through the De Novo pathway, creating a regulatory category for interoperable automated glycemic controllers. Tandem launched Control-IQ in the United States in January 2020 as a software update for compatible t:slim X2 pumps. The system uses CGM readings and a model-predictive algorithm to adjust basal insulin and deliver automatic correction boluses. Users remain responsible for therapy settings and generally announce meals. A randomized clinical trial published in 2019 found that participants using Control-IQ spent substantially more time in the 70–180 mg/dL target range than participants using sensor-augmented pump therapy. Tandem expanded its portfolio through acquisitions. It acquired Sugarmate in June 2020, adding a glucose-data and alert application. In July 2022, it acquired Capillary Biomedical for infusion-set technology. In January 2023, it acquired Swiss developer AMF Medical, whose Sigi rechargeable patch pump remained in development in the available source material. The company's second principal pump, Tandem Mobi, was designed as a smaller durable pump that could be worn on the body or carried in clothing. It uses a 200-unit cartridge, is operated mainly through a compatible smartphone application, and includes a physical button for a preset bolus. The FDA cleared Mobi in July 2023, Tandem launched it fully in the United States in February 2024, and the company obtained a CE mark in 2025 before beginning European introductions. Tandem has continued developing its data and software ecosystem. Its t:connect desktop application received FDA clearance in 2013, while later mobile functionality enabled users to view pump and CGM information and, in compatible configurations, deliver a bolus from a phone. Tandem Source, introduced in the United States in 2023, provides a web-based environment for patients and clinicians to review therapy data. Control-IQ+ broadened supported therapy settings and received clearance in 2025 for adults with insulin-treated type 2 diabetes. Because its products deliver insulin and depend on software, connectivity, alarms, and infusion components, Tandem has also faced regulatory corrections and recalls. A 2014 cartridge recall addressed possible leaks. Later FDA Class I recalls involved the t:connect iOS application, Control-IQ+ software, t:slim X2 speaker performance, and a Tandem Mobi vibration-motor condition. These actions illustrate the safety and reliability requirements attached to connected automated insulin-delivery systems. Tandem remains an active public company serving users in the United States and international markets. Tandem Diabetes is the brand identity used by Tandem Diabetes Care, Inc., a San Diego-based medical-device company serving the diabetes-care market. The available reference material does not document the company’s founding circumstances or early corporate history, so no specific founding date or founder is assigned in this entry. The company’s identifiable business focus is insulin delivery. Rather than operating as a general pharmaceutical or diagnostic brand, Tandem concentrates on insulin pumps and the technology and services that accompany pump-based diabetes management. Its product communications place equal attention on medical function and the everyday experience of using diabetes equipment, including convenience, usability, innovation, and appearance. The t:slim X2 insulin pump is the best-documented flagship offering associated with the brand. It represents Tandem’s central role in the insulin-pump segment and serves as the principal product through which the company communicates its approach to insulin delivery. Tandem also describes its scope as including other products and services for diabetes management, including software and connected elements, but the supplied materials do not provide enough detail to construct a verified chronology of those products or their regulatory milestones. Tandem operates from San Diego, California, and serves the United States as well as international markets. The company is publicly listed under the ticker TNDM. No verified information was supplied for its original ownership structure, parent company, founding team, executive succession, or detailed geographic expansion. Those subjects therefore remain open for further research rather than being filled with assumptions. The available sources likewise do not substantiate a detailed record of campaigns, scandals, recalls, lawsuits, mergers, acquisitions, or major strategic decisions. The absence of entries in those sections should not be interpreted as proof that no such events have occurred; it reflects the limited reference set used for this pass. A comprehensive historical treatment would need to consult company filings, regulatory databases, product approvals, investor communications, and reputable reporting. In its current form, Tandem Diabetes can be described as an active public medical-technology brand whose identity is built around insulin pumps and diabetes-management technology. Its public-facing proposition is to combine medical-device capability with a more convenient and connected daily experience for people using insulin therapy.
- 2025
Control-IQ+ expanded to insulin-treated type 2 diabetes
[1]A revised Control-IQ+ version received clearance for adults with type 2 diabetes who require insulin.
- 2023
Tandem Mobi receives FDA clearance
[1]The FDA cleared Tandem's smaller wearable Mobi insulin pump.
- 2020
Control-IQ launches in the United States
[1]Control-IQ became available as a software update for compatible t:slim X2 pumps.
- 2019
Control-IQ receives FDA authorization
[1]The FDA authorized Control-IQ through the De Novo pathway for interoperable automated glycemic control.
- 2018
Basal-IQ introduced
[1]Tandem introduced predictive low-glucose suspend functionality.
- 2016
t:slim X2 begins shipping
[1]Tandem began shipping the software-updatable t:slim X2 platform.
- 2015
t:slim G4 approved
[1]The t:slim G4 combined Tandem's pump platform with Dexcom G4 Platinum CGM display functionality.
- 2013
Nasdaq initial public offering
[1]Tandem became a publicly traded company on Nasdaq under the ticker TNDM.
- 2012
t:slim sales begin
[1]Tandem began selling the touchscreen t:slim pump in the United States.
- 2011
FDA clears the first t:slim system
[1]The FDA cleared Tandem's first t:slim insulin-delivery system in November.
Products and positioning
A connected diabetes-technology company emphasizing touchscreen and wearable insulin pumps, interoperability with continuous glucose monitors, software-updatable hardware, and automated insulin delivery. A diabetes-technology brand focused on insulin pumps and connected management tools, with an emphasis on innovation, convenience, usability, and design.
Insulin pump · 2016
t:slim X2
The t:slim X2 is a rechargeable touchscreen insulin pump using a 300-unit cartridge. It delivers programmed basal and bolus insulin through an infusion set and supports software updates without replacing the pump hardware. With a compatible CGM and Control-IQ technology, it can automatically adjust insulin delivery. The platform has supported Dexcom and, in some markets, FreeStyle Libre integrations. It became the core successor to earlier t:slim products and serves as Tandem's flagship insulin-delivery device.
Wearable insulin pump · 2023
Tandem Mobi
Tandem Mobi is a compact durable pump designed to be worn on the body or carried in clothing. It uses a 200-unit cartridge and is operated primarily through a compatible smartphone application. A physical button can deliver a preset bolus. The FDA cleared Mobi in 2023, followed by a full U.S. launch in 2024 and European market introductions after CE marking in 2025.
Automated insulin-delivery software · 2020
Control-IQ+
Control-IQ is a hybrid closed-loop technology that uses CGM readings and a model-predictive algorithm to increase, decrease, or suspend basal insulin and deliver automatic correction boluses. It is used with compatible Tandem pumps and sensors. Users retain responsibility for personal therapy settings and normally announce meals. The U.S. launch occurred in 2020 as a software update for t:slim X2. Control-IQ+ is a revised automated-delivery version that broadens supported therapy settings. In the United States it is used on t:slim X2 and Mobi platforms and received clearance in 2025 for adults with insulin-treated type 2 diabetes.
Predictive low-glucose suspend software · 2018
Basal-IQ
Basal-IQ uses predicted CGM values to suspend insulin delivery when glucose is expected to fall low and resumes delivery when readings recover. It represented Tandem's earlier step toward automated insulin delivery before Control-IQ.
Diabetes-management software · 2023
Tandem Source
Tandem Source is a web-based data platform introduced in the United States in 2023. It enables users and clinicians to review pump and therapy information and forms part of Tandem's connected software ecosystem.
Diabetes-management software · 2013
t:connect
t:connect is Tandem's pump and glucose-data management application family. The desktop and mobile versions allow review of therapy information, while compatible configurations support bolus delivery from a phone.
Glucose-data application
Sugarmate
Sugarmate is an application for viewing continuous glucose-monitoring data and receiving customizable alerts. Tandem acquired the application in 2020.
Rechargeable patch pump
Sigi
Sigi is a rechargeable patch-pump technology developed by Swiss company AMF Medical, acquired by Tandem in 2023. It was designed around prefilled insulin cartridges and remained in development in the available reference material.
Insulin pump
t:slim X2 insulin pump
Tandem’s flagship insulin-delivery device and the clearest representative of its brand. The t:slim X2 is intended for people who use pump-based insulin therapy and is positioned within Tandem’s broader portfolio of diabetes-management products and services. The supplied sources do not provide a verified launch date or a complete technical specification, so this entry describes its role without adding unverified feature claims.
Brand decisions
2023
Acquire AMF MedicalM&ABackground
Tandem sought a smaller patch-pump form factor to complement its established durable-pump platforms.
Action taken
Tandem acquired Swiss developer AMF Medical and its Sigi rechargeable patch-pump program.
Aftermath
Sigi remained under development in the available source material, while Tandem continued commercializing the Mobi platform.
2022
Acquire Capillary BiomedicalM&ABackground
Infusion-set performance is an important component of reliable insulin-pump therapy.
Action taken
Tandem acquired Capillary Biomedical and its infusion-set development capabilities.
Aftermath
The acquisition expanded Tandem's control over technology supporting insulin delivery beyond the pump itself.
2020
Acquire SugarmateM&ABackground
Tandem sought to broaden its pump-centered offering with patient-facing glucose-data and alert software.
Action taken
Tandem acquired Sugarmate, an application for monitoring glucose information and configuring alerts.
Aftermath
Sugarmate became part of Tandem's broader digital diabetes-management ecosystem.
2019
Pursue interoperable automated insulin delivery with Control-IQProduct launchBackground
Tandem's software-updatable t:slim X2 platform had established a base for adding automated-delivery capabilities without replacing pump hardware.
Action taken
The company obtained FDA authorization for Control-IQ through the De Novo pathway and launched it in the United States as an update for compatible t:slim X2 pumps.
Aftermath
Control-IQ became a central part of Tandem's connected pump strategy and expanded the company from conventional pump delivery into hybrid closed-loop therapy.
Recent events
- 2025
FDA classifies t:slim X2 speaker-related correction as a Class I recall[1]
Recall · Regulation
A defect could incorrectly interpolate glucose values after gaps in continuous glucose-monitoring data and lead to excessive or insufficient insulin delivery.
- 2025
FDA classifies Tandem Mobi vibration-motor correction as a Class I recall[1]
Recall · Regulation
Some Mobi pumps could falsely detect a vibration-motor failure and enter a non-operational state, stopping insulin delivery and glucose-monitoring sessions.
- 2024
FDA classifies t:connect iOS application correction as a Class I recall[1]
Recall · Regulation
Repeated crashes and relaunches could increase Bluetooth activity, drain a connected pump battery, and interrupt insulin delivery. The correction covered distributed installations of version 2.7.
- 2024
Tandem begins the full U.S. launch of Tandem Mobi[1]
Product launch
Tandem Mobi entered full U.S. commercial launch after receiving FDA clearance the previous year.
- 2023
Tandem acquires AMF Medical[1]
M&A
The company acquired Swiss patch-pump developer AMF Medical and its developing Sigi rechargeable patch-pump technology.
- 2023
FDA clears Tandem Mobi[1]
Product launch
The FDA cleared Tandem Mobi, a smaller wearable or pocket-carried insulin pump operated mainly through a smartphone application.
- 2022
Tandem acquires Capillary Biomedical[1]
M&A
Tandem acquired infusion-set developer Capillary Biomedical to expand its insulin-delivery component capabilities.
- 2020
Tandem launches Control-IQ in the United States[1]
Product launch
Control-IQ became available as a software update for compatible t:slim X2 pumps.
- 2020
Tandem acquires Sugarmate[1]
M&A
The company acquired Sugarmate, an application for viewing glucose data and receiving customizable alerts.
- 2019
John Sheridan succeeds Kim Blickenstaff as chief executive[1]
Leadership change
John Sheridan, previously Tandem's chief operating officer, became president and chief executive officer.
Showing the 10 most recent.
Sources5 sources
- 1Tandem Diabetes Careen.wikipedia.org
- 2Tandem Diabetes Care official websitetandemdiabetes.com
- 3Abbott partners with Omada, Tandem to extend the reach of its FreeStyle Libre CGMfiercebiotech.com
- 4CeQur Raises $115 Million Series C5 Financing to Support Commercialization and Scale-Up of Automated Manufacturing for CeQur Simplicity Wearable Insulin-Delivery Devicefinanznachrichten.de
- 5Dexcom Partners With Tandem Diabetes Care on the t:slim X2 Insulin Pump in the UK, Sweden, Italy and Spainprnewswire.co.uk
Cite this profile: Cite the canonical profile. /brand-wiki/tandem-diabetes-care · Editorial policy · How profiles are compiled